Acetylon Announces $15 Million Strategic Equity Investment by Celgene Corporation
HTML |
PDF
December 12, 2011
Acetylon Announces Publication of Preclinical Pharmacokinetic, Pharmacodynamic and Bone Disease Results for ACY-1215 in Multiple Myeloma
HTML | PDF
December 12, 2011
Acetylon Announces Addition of Catherine A. Wheeler MD
as Vice President Clinical Development
HTML | PDF
June 29, 2011
Acetylon Pharmaceuticals Announces Completion of
$27 Million Series B Round of Private Investor Financing
HTML | PDF
May 11, 2011
The Leukemia & Lymphoma Society and Acetylon Pharmaceuticals Partner to Advance the Clinical Development of Acetylon’s ACY-1215 Drug Candidate for Multiple Myeloma
HTML | PDF
April 25, 2011
Acetylon Pharmaceuticals Adds HDAC Biology, Inflammation and Neurodegeneration Experts to its Scientific Advisory Board
HTML | PDF
December 6, 2010
Acetylon Announces Publication of Preclinical Safety and Efficacy Results for Lead Drug Candidate ACY-1215 in Multiple Myeloma
HTML | PDF
November 11, 2010
Acetylon Pharmaceuticals Inc. Awarded Two Therapeutic Discovery Project Grants
HTML | PDF
March 8, 2010
Acetylon Licenses Powerful Discovery Methodology and Platform from Harvard University and the Dana-Farber Cancer Institute
HTML | PDF
March 8, 2010
Harvard University and Dana-Farber Cancer Institute Grant Acetylon Exclusive License to Breakthrough Discovery Platform for Next Generation HDAC Inhibitors
HTML | PDF
January 8, 2010
Acetylon Pharmaceuticals Tops Up Series A Financing with $2 Million Note And Appoints Simon Jones VP Biology and Preclinical Development and
John van Duzer VP Chemistry and Manufacturing
HTML | PDF
August 7, 2009
Acetylon Pharmaceuticals Raises $7.25 Million Series A
to Develop Next-Generation Selective HDAC Inhibitors
for Cancer and Rheumatoid Arthritis
HTML | PDF
